2024
Tafenoquine for Relapsing Babesiosis: A Case Series
Krause P, Rogers R, Shah M, Kang H, Parsonnet J, Kodama R, Vannier E. Tafenoquine for Relapsing Babesiosis: A Case Series. Clinical Infectious Diseases 2024, 79: 130-137. PMID: 38814096, PMCID: PMC11259219, DOI: 10.1093/cid/ciae238.Peer-Reviewed Original ResearchRelapsing babesiosisPolymerase chain reactionReal-time polymerase chain reactionImmunocompromised patientsTreatment of Plasmodium vivax malariaPlasmodium vivax malariaModel of acute infectionAntimicrobial agentsBlood smearsAnimal models of acute infectionsWeekly maintenance dosesAcquisition of resistanceAtovaquone-proguanilVivax malariaMalaria prophylaxisMaintenance doseLoading doseCase seriesDelayed clearanceAcute infectionTafenoquinePrevent relapseThin blood smearsLow dosesAnimal modelsAbsence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG)
Kostka J, Maharjan A, Kumar S, Hackenyos D, Krause P, Dieckhaus K. Absence of Anti-Babesia microti antibody in commercial intravenous immunoglobulin (IVIG). PLOS Neglected Tropical Diseases 2024, 18: e0012035. PMID: 38484010, PMCID: PMC10965045, DOI: 10.1371/journal.pntd.0012035.Peer-Reviewed Original ResearchConceptsIntravenous immunoglobulinB. microti antibodiesBabesiosis patientsSpectrum of disease severityCommercial intravenous immunoglobulinEffective treatment strategiesSevere organ damageHost antibody responseImmunocompromised patientsAdjunctive therapyOrgan damageTreatment strategiesAcute andClinical trialsMicroti antibodiesAsymptomatic infectionAntibody responseTherapeutic benefitTherapeutic effectPatientsDisease severityAntibodiesImmunofluorescence assayProtozoan infectionsCommercial samples
2010
Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection
Wormser GP, Prasad A, Neuhaus E, Joshi S, Nowakowski J, Nelson J, Mittleman A, Aguero-Rosenfeld M, Topal J, Krause PJ. Emergence of Resistance to Azithromycin-Atovaquone in Immunocompromised Patients with Babesia microti Infection. Clinical Infectious Diseases 2010, 50: 381-386. PMID: 20047477, DOI: 10.1086/649859.Peer-Reviewed Original ResearchConceptsDrug regimenB. microtiLevel of immunosuppressionBabesia microti infectionTreatment of babesiosisDrug-resistant strainsEmergence of resistanceActive babesiosisMicrobiologic relapseLaboratory abnormalitiesDrug regimensImmunocompromised patientsOptimal therapyTreatment failureDrug therapyMicroti infectionPatientsClinical case historiesDrug resistanceBabesia microtiInfectionRegimenMicrotiEventual developmentBabesiosis